Editorial: Machine learning approaches to antimicrobials: discovery and resistance

Shira L. Broschat, Shirley W. I. Siu, César de la Fuente‐NúñezFrontiers in Bioinformatics 2024 · DOI · OpenAlex

Introduction: The Global Crisis of Antimicrobial Resistance

In the early 20th century, infectious diseases were the leading cause of death in the United States, accounting for nearly 60% of mortality. The introduction of antibiotics in the mid-1900s fundamentally shifted this landscape, reducing that figure to just 1.62% by 2010. However, this medical triumph is currently under siege by the rise of antimicrobial resistance (AMR).

Today, AMR represents a critical public health threat. Millions of infections occur annually, many involving "superbugs" resistant to multiple classes of antibiotics. Globally, AMR is linked to over 1.27 million deaths each year. Despite the urgency, the pipeline for new antimicrobials has stalled. Large pharmaceutical companies are increasingly reluctant to invest in development due to high costs and low returns on investment. To bridge this "discovery void," researchers are turning to machine learning (ML) to reduce the expense and uncertainty of traditional drug discovery and diagnostic methods.

Addressing the Discovery and Detection Gaps

The fight against AMR faces two primary bottlenecks:

  1. The Discovery Gap: Conventional drug development is slow and prohibitively expensive, leading many firms to abandon the field.
  2. The Detection Gap: Traditional laboratory methods for identifying phenotypic resistance in clinical samples are time-consuming, often delaying the administration of effective treatments and contributing to further resistance.

Machine learning offers a "powerful incentive" for developers by providing tools that can predict antimicrobial activity and resistance patterns with high speed and accuracy, effectively bypassing traditional laboratory bottlenecks.

Methodological Innovations in ML

This Research Topic highlights five distinct studies utilizing diverse ML architectures to tackle AMR:

  • Supervised Learning for Peptide Discovery: Researchers employed Alternating Decision Trees and Support Vector Machines (SVM) to identify bacteriocins—natural antimicrobial peptides produced by bacteria—from genomic data.
  • K-mer Based Genomic Analysis: By analyzing short, fixed-length DNA sequences (k-mers) from Whole Genome Sequencing (WGS), tools like KARGVA can identify antibiotic resistance gene variants (ARGVs) and predict phenotypic resistance without relying solely on sequence alignment.
  • Deep Learning for Proteomics: Moving beyond DNA, the MSDeepAMR model utilizes Deep Neural Networks (DNNs) to analyze mass spectrometry data. This allows for the identification of proteomic signatures associated with resistance, potentially enabling real-time diagnostics in hospital settings.
  • Advanced Feature Selection: To improve model efficiency, algorithms based on game theory were used to isolate the most predictive biological markers, ensuring high accuracy with minimal computational overhead.

Data Sources and Clinical Specificity

The effectiveness of these ML models was validated across a range of biological datasets, including:

  • Clinical Genomic Strains: Data from 52 clinical strains of Helicobacter pylori and various Acinetobacter baumannii isolates.
  • Proteomic Profiles: Mass spectrometry data for common pathogens such as Escherichia coli, Staphylococcus aureus, and Klebsiella pneumoniae.
  • Public Repositories: Large-scale training sets for bacteriocin and antimicrobial peptide (AMP) identification.

A notable finding was the high clinical specificity achieved. For H. pylori, models reached 100% specificity for resistance to amoxicillin and clarithromycin, a critical metric for ensuring patients are not prescribed ineffective treatments.

Key Insights and Performance Benchmarks

The research demonstrates that ML can identify "hidden" resistance patterns that traditional tools like BLAST might miss because they do not rely strictly on sequence similarity. For example, using only the "top 11-mers" (specific short DNA sequences), models achieved 96% accuracy in predicting resistance across 13 different drugs in A. baumannii.

Other high-performing benchmarks include:

  • Bacteriocin Prediction: 99.11% accuracy (AUC of 0.9984).
  • Resistance Gene Variant Identification: The KARGVA tool maintained 99.2% accuracy even amidst genetic drift.
  • Deep Learning for AMR: MSDeepAMR significantly outperformed previous methods in predicting ciprofloxacin resistance across multiple species.

Challenges and Future Outlook

While ML provides a transformative toolkit, several hurdles remain. Many models are trained on relatively small datasets, which may limit their generalizability to diverse global bacterial populations. Furthermore, the "black box" nature of some deep learning models makes it difficult to interpret the underlying biological mechanisms of resistance.

Perhaps most importantly, ML-driven discovery still requires "wet lab" validation. Predicted antimicrobial candidates must undergo rigorous in vivo testing for safety and efficacy. Finally, while technology can lower the cost of discovery, systemic economic barriers—specifically the lack of financial return for pharmaceutical developers—require policy-level interventions alongside technological innovation.

The integration of ML into antimicrobial research marks a significant step toward a more agile and data-driven response to the AMR crisis, potentially securing the future of infectious disease treatment.

Summary updated

Abstract

Editorial on the Research Topic Machine learning approaches to antimicrobials: discovery and resistanceIn 1900, infectious diseases were responsible for nearly 60% of deaths in the United States.By 2010, this had dropped to only 1.62% (Jones et al., 2012).The reason for this dramatic decrease was the introduction of antibiotics in the mid-20th century.However, antimicrobial resistance (AMR) now jeopardizes this achievement.In fact, AMR is a major public health threat with millions of AMR infections occurring annually, often involving resistance to multiple antibiotics.In the United States, AMR accounts for more than 35,000 deaths each year and over 1.27 million deaths globally (CDC, 2024).Unfortunately, because of the high cost of development and lack of return on investment, large pharmaceutical companies are unwilling to commit to developing new antimicrobials to combat AMR without incentives (Dutescu and Hillier, 2021; WHO, 2023).Reducing the expense and uncertainty associated with conventional methods of drug discovery may serve as a powerful incentive.Machine learning (ML), a branch of artificial intelligence, can assist in the fight against AMR with the development of new antimicrobials (Torres et al.,
BibTeX
@inproceedings{broschat2024editorial,
  author = {Shira L. Broschat and Shirley W. I. Siu and César de la Fuente‐Núñez},
  title = {{Editorial: Machine learning approaches to antimicrobials: discovery and resistance}},
  booktitle = {Frontiers in Bioinformatics},
  year = {2024},
  doi = {10.3389/fbinf.2024.1458237},
}
Figure